Aravive (FRA:VE11) Net Issuance of Debt

: €0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Aravive's net issuance of debt for the three months ended in Sep. 2023 was €0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil.

Aravive Net Issuance of Debt Historical Data

The historical data trend for Aravive's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Issuance of Debt

Get a 7-Day Free Trial

1.67

Aravive Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Issuance of Debt	Get a 7-Day Free Trial															-	-	-	-	-

Aravive Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Aravive Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Aravive's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Aravive (FRA:VE11) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (FRA:VE11) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

ARAV:USA

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (FRA:VE11) Headlines

No Headlines